We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (384)
- Scheduling (national classification system) (164)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
761 result(s) found, displaying 76 to 100
-
Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories
TGA laboratory testing reportsThe TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna). -
Corporate reportsWe commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsRead the meeting statement from 10 October 2024 meeting of the Advisory Committee on Medical Devices
-
Meeting statementsA meeting statement from the second meeting of the Point-of-care Manufacturing of Medical Devices Steering Committee is now available.
-
Meeting statementsFind out about the AIVC Recommendations for the Composition of Influenza Vaccines for Australia in 2025.
-
Scheduling submissionsFind out about the public submissions on interim decisions for scheduling matters referred to the ACMS #44, ACCS #38 and Joint ACMS-ACCS #36 meetings held in March 2024
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (final)Publication of the decisions made by a delegate of the Secretary in relation to glycopyrronium and palmitoylethanolamide.
-
Scheduling decisions (interim)Interim decisions on proposed amendments to the Poisons Standard closing 18 October 2024.
-
Scheduling decisions (final)This publication is a notice of decision made by a delegate of the Secretary of the Department of Health and Aged Care under regulation 42ZCZX of the Therapeutic Goods Regulations 1990, and the reasons for the decision.
-
Meeting statementsCommunique from the 7th meeting of the WHPWG 30 July 2024
-
Meeting statementsRead key points of discussion from the meeting 14 of the Medical Devices Consumer Working Group (MDCWG).
-
Meeting statementsThe 80th meeting of the Advisory Committee on Medical Devices (ACMD), 8 August 2024.
-
Corporate reportsRead our business plan 2024-25 to find out about our strategic priorities and activities.
-
Corporate reportsFind out how we are managing shortages of medicines and taking action to limit their effects. Read our 2024 report.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 23 August 2024
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #44, ACCS #38 and Joint ACMS-ACCS #36 meetings held in March 2024
-
Corporate reportsDocuments released under the FOI Act in the 2023/24 financial year
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsRead the meeting statement from 27 June 2024 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2024-2025 provides information on how we implement, and cost recover our regulatory activities.
-
Meeting statementsCommunique from the 6th meeting of the WHPWG, 27 March 2024
-
TGA laboratory testing reportsMedicinal cannabis products are permitted to be supplied into Australia under the Special Access Scheme, by authorised prescribers, and/or for use in clinical trials.